RTRX vs. EPIX, CTNM, CRMD, NBTX, ENTA, VNDA, INZY, HOWL, XOMA, and VRCA
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include ESSA Pharma (EPIX), Contineum Therapeutics (CTNM), CorMedix (CRMD), Nanobiotix (NBTX), Enanta Pharmaceuticals (ENTA), Vanda Pharmaceuticals (VNDA), Inozyme Pharma (INZY), Werewolf Therapeutics (HOWL), XOMA (XOMA), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "medical" sector.
Travere Therapeutics (NASDAQ:RTRX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
ESSA Pharma has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. ESSA Pharma's return on equity of -17.41% beat Travere Therapeutics' return on equity.
Travere Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.
ESSA Pharma has a consensus price target of $16.50, suggesting a potential upside of 139.83%. Given ESSA Pharma's higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Travere Therapeutics.
Travere Therapeutics received 72 more outperform votes than ESSA Pharma when rated by MarketBeat users. However, 76.32% of users gave ESSA Pharma an outperform vote while only 73.17% of users gave Travere Therapeutics an outperform vote.
75.1% of ESSA Pharma shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by insiders. Comparatively, 14.7% of ESSA Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ESSA Pharma has lower revenue, but higher earnings than Travere Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Travere Therapeutics' average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score.
Summary
ESSA Pharma beats Travere Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
